In patients with NS due to PTPN11 or KRAS mutations associated with myeloproliferative disorder (MPD)/JMML, 3- to 6-monthly CBC with spleen size assessment should be considered starting at birth and continuing until the age of 5 [69]. The gene discussed is KRAS; the disease is myeloproliferative neoplasm.